Category: bromides-buliding-blocks

On July 22, 1999, Stolle, Andreas; Antonicek, Horst-Peter; Lensky, Stephen; Voerste, Arnd; Muller, Thomas; Baumgarten, Jorg; Von Dem Bruch, Karsten; Muller, Gerhard; Stropp, Udo; Horvath, Ervin; De Vry, Jean-Marie Viktor; Schreiber, Rudy published a patent.SDS of cas: 259231-26-0 The title of the patent was Preparation of 6-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-ones as metabotropic glutamate receptor modulators.. And the patent contained the following:

Title compounds [I; A = CH2, CO, CR4OH, (CH2)aCHR5, alkylene, alkenylene, alkynylene; a = 0-4; R4 = H, alkyl; R5 = Ph; R1 = H, (substituted) cycloalkyl, heterocyclyl, benzoheterocyclyl, aryl, etc.; R2, R3 = H, alkyl; DE = CH2C(:CR32R31)CH2, CR33:CR34CHR35, etc.; R31-R35 = H, Ph, alkyl], were prepared for preventing and/or treating diseases caused by the hyper- or hypofunction of the glutamatergic system, especially cerebral ischemia, cranial/cerebral trauma, pain or CNS-mediated cramps (no data). Thus, 2-methoxycarbonyl-4-methylidenecyclopentanecarboxylic acid in THF at -15° was treated with Et3n and EtO2CCl followed by 1 h stirring at room temperature The mixture was filtered and the filtrate in MeOH at -15° was treated with NaBH4 followed by 1 h stirring at room temperature to give 58% (3aS*,6aR*)-5-methylidenehexahydrocyclopenta[c]furan-1-one. The latter in PhMe was was added to LiN(SiMe3)2 in THF/PhMe at -78° followed by warming to room temperature, 1 h stirring, and addition of PhCH2Br to give 68% (3aS*,6aR*)-6a-benzyl-5-methylidenehexahydrocyclopenta[c]furan-1-one. The experimental process involved the reaction of 2-Bromo-4-(bromomethyl)-1-methylbenzene(cas: 259231-26-0).SDS of cas: 259231-26-0

The Article related to benzylmethylidenehexahydrocyclopentafuranone preparation metabotropic glutamate receptor modulator, cyclopentafuranone benzyl methylidene preparation metabotropic glutamate receptor modulator, analgesic benzylmethylidenehexahydrocyclopentafuranone, head trauma treatment benzylmethylidenehexahydrocyclopentafuranone and other aspects.SDS of cas: 259231-26-0

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Turksoy, Abdurrahman; Scattolin, Thomas; Bouayad-Gervais, Samir; Schoenebeck, Franziska published an article in 2020, the title of the article was Facile Access to AgOCF3 and Its New Applications as a Reservoir for OCF2 for the Direct Synthesis of N-CF3, Aryl or Alkyl Carbamoyl Fluorides.Safety of 4-(Bromomethyl)-1,1′-biphenyl And the article contains the following content:

Herein, a straightforward and quant. strategy for the preparation of valuable AgOCF3 at room temperature and showcase its performance in trifluoromethoxylations or as reservoir for O=CF2 was showed. This enabled the direct, practical and safe synthesis of valuable N-alkyl/aryl carbamoyl fluorides and N-CF3 carbamoyl fluorides from secondary amines and isothiocyanides, resp. Mechanistic data indicated that AgOCF3 does not liberate O=CF2 until it was activated by a nucleophilic co-reagent, reinforcing the stability of the salt under new preparation strategy. The experimental process involved the reaction of 4-(Bromomethyl)-1,1′-biphenyl(cas: 2567-29-5).Safety of 4-(Bromomethyl)-1,1′-biphenyl

The Article related to silver trifluoromethoxide green preparation, trifluoromethyl ether preparation, alkyl halide silver trifluoromethoxide substitution, alc alkyl silver trifluoromethoxide dehydrotrifluoromethoxylation, carbamoyl fluoride preparation, n-trifluoromethyl, carbamoyl fluorides, fluorination, mechanism, synthetic methods and other aspects.Safety of 4-(Bromomethyl)-1,1′-biphenyl

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On February 7, 2018, Neuzil, Jiri; Werner, Lukas; Stursa, Jan published a patent.Application of 83152-22-1 The title of the patent was Triphenylphosphonium biguanide analogs, the method of their preparation and their use as a medication. And the patent contained the following:

Biguanides R5R4NC(:NR6)NR3C(:NR7)NR1R2·HX (1, R1-R7 = H, C1-6 alkyl, aralkyl, or substituent ZPPh3+Y-, where Z = linear C2-C20 alkylene, preferably, C8-12 alkylene), useful as antidiabetic agents, for treatment of Diabetes mellitis type II, and diabetes-induced tumors, were prepared by quaternization of PPh3 with 1,ω-dihaloalkanes XZX (2, X = halo), amination of resulting haloalkylphosphonium salts XZPPh3+X- with ammonia or primary amines R1NH2 and reaction with cyanoguanidines R5R4NC(:NR6)NCN. The prepared compounds 1 were examined for growth inhibition and apoptosis of pancreatic cell lines, for suppression of mitochondrial respiration through inhibition of complex I and increase of production of ROS. The experimental process involved the reaction of (6-Bromohexyl)triphenylphosphonium bromide(cas: 83152-22-1).Application of 83152-22-1

The Article related to biguanide phosphonium salt derivative preparation antidiabetic antitumor agent, pancreatic tumor cell line inhibition biguanide phosphonium salt, mitochondrial respiration inhibition tumor cell line biguanide phosphonium salt, reactive oxygen species generation tumor cell line biguanide phosphonium and other aspects.Application of 83152-22-1

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On April 14, 2022, Kuduk, Scott; Pietsch, Eva Christine; Guttke, Christina D.; Bush, Tammy L. published a patent.Related Products of 1003709-39-4 The title of the patent was Preparation of substituted isoquinolinones as dihydroorotate dehydrogenase inhibitors for use in combinations with hypomethylating agents. And the patent contained the following:

Disclosed are methods of treating a subject who has been diagnosed with a disease, syndrome, condition, or disorder affected by DHODH enzymic activity comprising administering: a therapeutically effective amount of a DHODH inhibitor I [X = CH or N; Y = CH or N; R1 = (un)substituted alkyl, haloalkyl, cycloalkyl, etc.; R2 = II (wherein Ra = alkyl, haloalkyl, cycloalkyl; Rb = (un)substituted alkyl); R3 = H, halo, Me and OMe; R4 = (un)substituted alkyl, cycloalkyl, pyridyl, etc.], a therapeutically effective amount of a hypomethylating agent and optionally, a therapeutically effective amount of a BCL-2 inhibitor. E.g., a multi-step synthesis of III, starting from Et 2-(benzyloxy)acetate and hydrazine hydrate, was described. The latter was assessed for its ability to induce cytotoxicity in 30 primary AMF patient samples by Cell TiterGlo assay. Eighteen of the AMF samples were highly sensitive to the compound III resulting in IC50 values between 0.11 and 95.1 nM, one patient sample had an IC50 value of 469.1 nM and the remaining 11 cases demonstrated little sensitivity to III with the highest concentration evaluated (3000 nM) unable to kill more than 50% of the tumor cells. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Related Products of 1003709-39-4

The Article related to isoquinolinone preparation dihydroorotate dehydrogenase inhibitor combination chemotherapy hypomethylating agent, dhodh inhibitor combination chemotherapy hypomethylating agent isoquinolinone preparation, combination chemotherapy dhodh bcl2 inhibitor hypomethylating agent isoquinolinone preparation and other aspects.Related Products of 1003709-39-4

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 1, 2018, Erokhina, Svetlana A.; Stogniy, Marina Yu.; Suponitsky, Kyrill Yu.; Kosenko, Irina D.; Sivaev, Igor B.; Bregadze, Vladimir I. published an article.COA of Formula: C10H8BrNO2 The title of the article was Synthesis of new nido-carborane based carboxylic acids and amines. And the article contained the following:

New nido-carborane based carboxylic acids 10-HOOC(CH2)n(Me)S-7,8-C2B9H11 (n = 1-4) were prepared by alkylation of Bu4N salt of 10-methylthio-7,8-dicarba-nido-borane with ω-haloalkyl esters or nitriles followed by acid hydrolysis. Likewise nido-carborane based amines 10-H2N(CH2)n(Me)S-7,8-C2B9H11 (n = 2, 3) were obtained using ω-bromoalkylphthalimides as alkylating agents followed by removal of the protecting group with hydrazine. Structure of 10-C6H4(CO)2NCH2CH2(Me)S-7,8-C2B9H11 was determined by single crystal x-ray diffraction. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).COA of Formula: C10H8BrNO2

The Article related to amine carboranylthioalkyl derivative preparation, carboxylic acid carboranylthioalkyl derivative preparation, carboranyl thioalkylphthalimide preparation crystal structure reaction hydrazine, mol structure carboranyl thioalkylphthalimide, alkylation thiodicarbaborane haloalkyl ester nitrile and other aspects.COA of Formula: C10H8BrNO2

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On February 10, 2022, Chen, Chen published a patent.Related Products of 111010-07-2 The title of the patent was Preparation of cyclic iminopyridimdine compounds and their bicyclic derivatives as kinase inhibitors and uses thereof. And the patent contained the following:

Provided are the title compounds I [G1 = N or CRa; G2 = N or CRb; n = 1 or 2; m = 0-3; Ra and Rb = (independently) H, halo, CN, etc.; each R1 = (independently) halo, (un)substituted alkyl, alkoxy; or two R1 groups with the carbon atom they connect to form (un)substituted 4-7 membered carbocyclic or heterocyclic ring; R2 = H, (un)substituted alkyl, alkoxy, etc.; R3 = H, halo, (un)substituted alkyl, alkoxy; R4 = H, (un)substituted alkyl, heterocyclyl, etc.; and R5 = H, alkyl, or heterocyclyl; or NR4R5 = (un)substituted heterocyclyl or heteroaryl; with the provisos] or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MAPK, PDGFR, Src, PAKs, c-Kit, EphA2, EphB4, FGFR, Axl, and c-Met. E.g., a multi-step synthesis of II, starting from 4-amino-2-(methylthio)pyrimidine-5-carboxaldehyde and Me 2-(2,4-dichlorophenyl)acetate, was described. The effect of the exemplified compounds I on the activity of various kinases were assessed (data given for representative compounds I). The experimental process involved the reaction of 5-Bromo-4-chloro-2-fluoroaniline(cas: 111010-07-2).Related Products of 111010-07-2

The Article related to cyclic iminopyrimidine bicyclic derivative preparation kinase inhibitor antitumor, mapk pdgfr src pak kinase inhibitor imidazopyridopyrimidinamine pyridodipyrimidinamine preparation, ckit epha2 ephb4 kinase inhibitor imidazopyridopyrimidinamine pyridodipyrimidinamine preparation antitumor and other aspects.Related Products of 111010-07-2

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

Mumtaz, Saira; Robertson, Mark J.; Oelgemoller, Michael published an article in 2019, the title of the article was Continuous flow photochemical and thermal multi-step synthesis of bioactive 3-arylmethylene-2,3-dihydro-1H-isoindolin-1-ones.Quality Control of 2-(2-Bromoethyl)isoindoline-1,3-dione And the article contains the following content:

An effective multi-step continuous flow approach towards N-(diamino)alkylated 3-arylmethylene-2,3-dihydro-1H-isoindolin-1-ones I [R = H, Me, OMe, F, R1 = Me, Et, X = (CH2)n, n = 2, 3], including the local anesthetic compound AL-12, has been realized. Compared to the traditional decoupled batch processes, the combined photochem.-thermal-thermal flow setup rapidly provides the desired target compounds I in superior yields and significantly shorter reaction times. The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Quality Control of 2-(2-Bromoethyl)isoindoline-1,3-dione

The Article related to arylmethylene isoindolinone preparation continuous flow photochem thermal, bromoalkyl phthalimide arylactetate continuous flow photochem thermal reaction, arylmethylene isoindolinones, continuous-flow photochemistry, multi-step synthesis, photochemistry, photodecarboxylation, phthalimide and other aspects.Quality Control of 2-(2-Bromoethyl)isoindoline-1,3-dione

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On May 22, 2014, Dominique, Romyr; Lopez-Tapia, Francisco Javier; Mertz, Eric; So, Sung-Sau published a patent.Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid The title of the patent was Preparation of substituted pyridinones as inhibitors of bruton’s tyrosine kinase. And the patent contained the following:

The title compounds I [A = (un)substituted unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl; R1 = halo, hydroxyalkyl, alkyl; m = 0-2; R2 = Me, pyrazolyl; n = 0-1; X = a bond, CH2, NHC(O)], useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity, were prepared E.g., a multi-step synthesis of II, starting from 6-tert-butyl-8-fluoro-2H-phthalazin-1-one and 1-bromo-4-chloromethylbenzene, was described. Exemplified compounds I were evaluated for their Btk inhibitory activity (data given). The compounds I are useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds I and at least one carrier, diluent or excipient. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid

The Article related to pyridinone phthalazinone preparation bruton’s tyrosine kinase btk inhibitor antiinflammatory, phthalazinone oxopyridinylbenzyl preparation auto immune disease aberrant bcell proliferation, rheumatoid arthritis treatment antirheumatic pyridinone phthalazinone preparation btk inhibitor and other aspects.Recommanded Product: 2-Bromo-4-fluoro-5-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary

On October 15, 2015, Dominique, Romyr; Lopez-Tapia, Francisco Javier; Mertz, Eric; So, Sung-Sau published a patent.Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid The title of the patent was Inhibitors of bruton’s tyrosine kinase. And the patent contained the following:

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. The experimental process involved the reaction of 2-Bromo-4-fluoro-5-methylbenzoic acid(cas: 1003709-39-4).Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid

The Article related to pyridinone phthalazinone preparation brutons tyrosine kinase btk inhibitor antiinflammatory, phthalazinone oxopyridinylbenzyl preparation auto immune disease aberrant bcell proliferation, rheumatoid arthritis treatment antirheumatic pyridinone phthalazinone preparation btk inhibitor and other aspects.Application In Synthesis of 2-Bromo-4-fluoro-5-methylbenzoic acid

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary